Is DSGN or EBS more undervalued in 2026?

CirclFi compares Design Therapeutics, Inc. (DSGN) and Emergent BioSolutions Inc. (EBS) using 13 institutional-grade valuation models. DSGN has a Quality of Company score of 4.1/10 while EBS scores 8.3/10.

Which is a better buy — DSGN or EBS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DSGN and EBS valuations compare?

DSGN at $10.48 and EBS at $9.12 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DSGN vs EBS Valuation Comparison 2026 — Intrinsic Value Analysis

DSGN

Pharmaceutical Preparations

Design Therapeutics, Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$10.48

Last close

Models

7/13

Active

EBS

Pharmaceutical Preparations

Emergent BioSolutions Inc.

Quality

8.3

out of 10

Value Trap

SAFE

Price

$9.12

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	DSGN Fair Value	DSGN Upside	EBS Fair Value	EBS Upside
Bayesian DCF	Intrinsic	$3.02	-71.1%	$27.60	+202.6%
Earnings Power Value	Intrinsic	—	—	$52.15	+471.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.57	-94.6%	$17.76	+94.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DSGN vs EBS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DSGN vs EBS — Which Stock Is More Undervalued?

EBS scores higher with a 8.3/10 quality rating vs DSGN's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Design Therapeutics, Inc. (DSGN) and Emergent BioSolutions Inc. (EBS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DSGN currently trades at $10.48 with a QOC of 4.1/10, while EBS trades at $9.12 with a QOC of 8.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).